Towards Advanced iPSC-based Drug Development for Neurodegenerative Disease

被引：34

作者：

Pasteuning-Vuhman, Svetlana ^{[1
]}

de Jongh, Rianne ^{[1
]}

Timmers, Annabel ^{[1
]}

Pasterkamp, R. Jeroen ^{[1
]}

机构：

[1] Univ Utrecht, Univ Med Ctr, Dept Translat Neurosci, Utrecht Brain Ctr, Utrecht, Netherlands

来源：

TRENDS IN MOLECULAR MEDICINE | 2021年 / 27卷 / 03期

关键词：

FAMILIAL ALZHEIMERS-DISEASE; BLOOD-BRAIN-BARRIER; 3-DIMENSIONAL CELL-CULTURE; STEAROYL-COA DESATURASE; MOTOR-NEURONS; STEM-CELLS; MODEL; ALS; REVEALS; INHIBITION;

D O I：

10.1016/j.molmed.2020.09.013

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Neurodegenerative diseases (NDDs) are a heterogeneous group of diseases that are characterized by the progressive loss of neurons leading to motor, sensory, and/or cognitive defects. Currently, NDDs are not curable and treatment focuses on alleviating symptoms and halting disease progression. Phenotypic heterogeneity between individual NDD patients, lack of robust biomarkers, the limited translational potential of experimental models, and other factors have hampered drug development for the treatment of NDDs. This review summarizes and discusses the use of induced pluripotent stem cell (iPSC) approaches for improving drug discovery and testing. It highlights challenges associated with iPSC model ing and also discusses innovative approaches such as brain organoids and microfluidic-based technology which will improve drug development for NDDs.

引用

页码：263 / 279

页数：17

共 50 条

[41] Engineering considerations of iPSC-based personalized medicine
Sangbae Park
Yonghyun Gwon
Shahidul Ahmed Khan
Kyoung-Je Jang
Jangho Kim
Biomaterials Research, 27
[42] Patient iPSC-based high throughput drug screening identifies drug candidates involved in reduced tauopathy associated with Alzheimer's disease
Gohel, Dhruv
Li, Yichen
Cheng, Feixiong
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
[43] iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation
Tristan-Noguero, Alba
Fernandez-Carasa, Irene
Calatayud, Carles
Bermejo-Casadesus, Cristina
Pons-Espinal, Meritxell
Baldeschi, Arianna Colini
Campa, Leticia
Artigas, Francesc
Bortolozzi, Analia
Domingo-Jimenez, Rosario
Ibanez, Salvador
Pineda, Merce
Artuch, Rafael
Raya, Angel
Garcia-Cazorla, Angels
Consiglio, Antonella
EMBO MOLECULAR MEDICINE, 2023, 15 (03)
[44] Development of Artificial Tumorigenesis Model From iPSC-Based Neural Crest Cells
Mukae, Kyosuke
Takenobu, Hisanori
Kanda, Hiroaki
Ohira, Miki
Endo, Yuki
Haruta, Masayuki
Toguchida, Junya
Osafune, Kenji
Nakahata, Tatsutoshi
Kamijo, Takehiko
PEDIATRIC BLOOD & CANCER, 2020, 67
[45] Integration of Nonlinear Analysis and Artificial Intelligence for Human Ipsc-based Drug Cardiotoxicity Classification
Ma, Zhen
Kowalczewski, Andrew
CIRCULATION, 2021, 144
[46] Development of iPSC-based models to test microglia-directed gene therapy for neurodegeneration
Nubie', M.
Hruska-Plochan, M.
Gatta, B.
Polymenidou, M.
Raimondi, F.
Pastukhov, O.
Wrona, D.
Jinek, M.
Greter, M.
Modlich, U.
Siler, U.
Reichenbach, J.
HUMAN GENE THERAPY, 2024, 35 (3-4) : A134 - A135
[47] Genetic Correction of Phospholamban Mutation in an iPSC-Based Disease Model of Familial Dilated Cardiomyopathy
Nonnenmacher, Mathieu E.
Karakikes, Ioannis
Stillitano, Francesca
Weber, Thomas
Hajjar, Roger J.
MOLECULAR THERAPY, 2014, 22 : S193 - S193
[48] iPSC-based gene therapy of congenital erythropoietic porphyria
Bedel, A.
Taillepierre, M.
Guyonnet-Duperat, V.
Dubus, P.
Thibaud, T.
Cardinaud, B.
Ged, C.
de Verneuil, H.
Moreau-Gaudry, F.
HUMAN GENE THERAPY, 2012, 23 (10) : A40 - A40
[49] Current challenges of iPSC-Based cardio oncology research
Kanda, Yasunari
CANCER SCIENCE, 2021, 112 : 199 - 199
[50] Modeling Pediatric Epilepsy Through iPSC-Based Technologies
Simkin, Dina
Kiskinis, Evangelos
EPILEPSY CURRENTS, 2018, 18 (04) : 240 - 245

← 1 2 3 4 5 →